top of page

Our Strategy

Utilizing biological mediators and pathways, FibroGen is accelerating a pipeline of treatments focusing on cancer and its related conditions.

Our near-term strategies include:

​​

  • Initiation of a Phase II trial of FG-3246 for metastatic castration-resistant prostate cancer in the second half of 2024.

  • Continue to progress our Phase 3 development plan in anemia associated with lower-risk myelodysplastic syndromes ("MDS").

 

Our Leadership

We are putting substantial expertise to work in
developing and commercializing novel therapeutics.
 

bottom of page